Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7882078 | 1.00 | MEN1 (0.65) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL15723436 | 1.00 | MEN1 (0.65) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL18251805 | 0.90 | MEN1 (0.58) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL23417829 | 0.90 | MEN1 (0.76) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12571330 | 0.90 | MEN1 (0.76) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL15082199 | 0.90 | MEN1 (0.76) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12787794 | 0.88 | MEN1 (0.69) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL9945627 | 0.88 | MEN1 (0.69) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12762769 | 0.88 | MEN1 (0.69) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL18251802 | 0.87 | MEN1 (0.67) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| CN-119866342-A | Cyclic peptides for capturing interleukin-1 beta | 默沙东有限责任公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024215820-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3210627-B1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO LTD (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-20220204495-A1 | INHIBITING TRABID | Valo Health, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3854789-A1 | MACROCYCLIC COMPOUNDS USEFUL AS CHITINASE INHIBITORS | CYGNET BIOSCIENCES B.V. (CW) | 2021-07-28 | — | — | EP | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020227168-A1 | INHIBITING TRABID | INTEGRAL EARLY DISCOVERY, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227168-A1 | INHIBITING TRABID | INTEGRAL EARLY DISCOVERY, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-9150899-B2 | Identification of compounds modifying a cellular response | 2CUREX (DK) | 2015-10-06 | — | — | US | disclosed |
| US-20130123140-A1 | IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE | 2CUREX (DK) | 2013-05-16 | — | — | US | disclosed |
| WO-2012025502-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | MEN1 2346/4885GAA 197/4885KMT2A 3520/4885 |
| US-20220204495-A1 | INHIBITING TRABID | TPO, PRKACG, NFKBIA | MEN1 1395/4885GAA 381/4885KMT2A 4796/4885 |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | POLRMT, MPI, PPIF | MEN1 563/4885GAA 1214/4885KMT2A 1205/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | MEN1 2346/4885GAA 197/4885KMT2A 3520/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | MEN1 2346/4885GAA 197/4885KMT2A 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.